SCHEMBL1887052

SCHEMBL1887052

CCOC(=O)n1nc2c(c1NC(=O)c1ccc(CN3CCCC3)cc1[N+](=O)[O-])CN(S(=O)(=O)c1cc(F)cc(F)c1)CC2(C)C

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
GAA P10253 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
TP53 P04637 3/20 0.33
TRPM8 Q7Z2W7 1/20 0.33
TRPV4 Q9HBA0 1/20 0.33
USP2 O75604 1/20 0.33
POLB P06746 1/20 0.33
EGFR P00533 1/20 0.32
LMNA P02545 4/20 0.32
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
THRB P10828 1/20 0.32
MAPT P10636 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2458227 0.87 ALDH1A1 (0.39) L3MBTL1MEN1KMT2AGAATDP1
SCHEMBL1893236 0.86 IGF1R (0.41) L3MBTL1MEN1KMT2AGAAPOLB
SCHEMBL1891377 0.85 MAPT (0.38) MEN1KMT2AGAATDP1TP53
SCHEMBL1892811 0.82 L3MBTL1 (0.35) L3MBTL1TDP1TP53EGFRLMNA
SCHEMBL2678711 0.81 L3MBTL1 (0.36) L3MBTL1GAATDP1TP53EGFR
Hydrochloric Acid SCHEMBL2678708 0.80 L3MBTL1 (0.35) L3MBTL1GAATDP1TP53EGFR
SCHEMBL1370894 0.79 MAPT (0.38) L3MBTL1MEN1KMT2AGAATDP1
SCHEMBL1886723 0.79 SMN1; SMN2 (0.36) L3MBTL1MEN1KMT2ATP53USP2
SCHEMBL1372170 0.77 KDM4E (0.39) L3MBTL1MEN1KMT2AGAATDP1
SCHEMBL1887045 0.77 IGF1R (0.43) MEN1KMT2AGAAUSP2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173659-B2 Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-05-08 US disclosed
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-22 US disclosed
US-7947686-B2 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-24 US disclosed
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K3, MAP3K1, MAP3K19 L3MBTL1 3525/4885MEN1 3780/4885KMT2A 1468/4885
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors MAP3K3, MAP3K1, MAP3K19 L3MBTL1 3525/4885MEN1 3780/4885KMT2A 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.